LOGIN  |  REGISTER
Astria Therapeutics

DocGo to Announce Fourth Quarter and Full Year 2023 Results on Wednesday, February 28, 2024

February 13, 2024 | Last Trade: US$1.50 0.06 -3.85
  • Management to host conference call and webcast at 5:00 p.m. ET on that day

NEW YORK / Feb 13, 2024 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the markets close on Wednesday, February 28, 2024. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day.

Conference call and webcast details:

Wednesday, February 28, 2024
5:00 p.m. ET
1-877-407-0784 (U.S.)
1-201-689-8560 (international)
Conference ID: 13743132
To access the Call me™ feature, which avoids the need to wait for an operator, click here.

A webcast of the conference call can be accessed under Events on the Investors section of the Company’s website at https://ir.docgo.com/.

About DocGo

DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo disrupts the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's proprietary, AI-powered technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit docgo.com.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page